Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lars W P, van der Laan"'
Autor:
Bo Zhang, Youyi Fong, Jonathan Fintzi, Eric Chu, Holly E. Janes, Avi Kenny, Marco Carone, David Benkeser, Lars W. P. van der Laan, Weiping Deng, Honghong Zhou, Xiaowei Wang, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Haiyan Chen, Isabel Reeder, Lindsay N. Carpp, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Chuong Huynh, Carl J. Fichtenbaum, Spyros Kalams, Cynthia L. Gay, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Frances Priddy, Rituparna Das, Bethany Girard, Hana M. El Sahly, Lindsey R. Baden, Thomas Jones, Ruben O. Donis, Richard A. Koup, Peter B. Gilbert, Dean Follmann, On behalf of the United States Government (USG) COVID-19 Immune Assays Team, Moderna, Inc. Team, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team, USG/CoVPN Biostatistics Team
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection against Ancestral-lineage COVI
Externí odkaz:
https://doaj.org/article/3b5ac665acef48f6bef0aa0502ebe57b
Autor:
David Benkeser, Youyi Fong, Holly E. Janes, Elizabeth J. Kelly, Ian Hirsch, Stephanie Sproule, Ann Marie Stanley, Jill Maaske, Tonya Villafana, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Victor Ayala, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, Lindsay N. Carpp, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Margaret Brewinski Isaacs, Mamodikoe Makhene, Tina Tong, Merlin L. Robb, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Corey Hoffman, Ann R. Falsey, Magdalena Sobieszczyk, Richard A. Koup, Ruben O. Donis, Peter B. Gilbert, on behalf of the AstraZeneca AZD1222 Clinical Study Group, the Immune Assays Team, the United States Government (USG)/CoVPN Biostatistics Team
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the U.S., Chile, and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured four weeks after two d
Externí odkaz:
https://doaj.org/article/4081698c1e354ea79e55b3bd26cbe811
Autor:
Youyi Fong, Yunda Huang, David Benkeser, Lindsay N. Carpp, Germán Áñez, Wayne Woo, Alice McGarry, Lisa M. Dunkle, Iksung Cho, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Julia Hutter, Maryam Keshtkar-Jahromi, Tatiana H. Beresnev, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Julie A. Ake, Cynthia L. Gay, Karen L. Kotloff, Richard A. Koup, Ruben O. Donis, Peter B. Gilbert, Immune Assays Team, Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team, United States Government (USG)/CoVPN Biostatistics Team
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Authors have previously reported on the efficacy and safety of the recombinant spike protein nanoparticle vaccine, NVX-CoV2373, in healthy adults. In this work, they assess anti-spike binding IgG, anti-RBD binding IgG and neutralising antibody titer
Externí odkaz:
https://doaj.org/article/f3590fa9e20145b28dc93b73d492a237
Autor:
Youyi Fong, Yunda Huang, David Benkeser, Lindsay N. Carpp, Germán Áñez, Wayne Woo, Alice McGarry, Lisa M. Dunkle, Iksung Cho, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Julia Hutter, Maryam Keshtkar-Jahromi, Tatiana H. Beresnev, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Julie A. Ake, Cynthia L. Gay, Karen L. Kotloff, Richard A. Koup, Ruben O. Donis, Peter B. Gilbert, Immune Assays Team, Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team, United States Government (USG)/CoVPN Biostatistics Team
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/b85419e23d814712a753f2591916bbfa
Autor:
Peter B, Gilbert, David C, Montefiori, Adrian B, McDermott, Youyi, Fong, David, Benkeser, Weiping, Deng, Honghong, Zhou, Christopher R, Houchens, Karen, Martins, Lakshmi, Jayashankar, Flora, Castellino, Britta, Flach, Bob C, Lin, Sarah, O'Connell, Charlene, McDanal, Amanda, Eaton, Marcella, Sarzotti-Kelsoe, Yiwen, Lu, Chenchen, Yu, Bhavesh, Borate, Lars W P, van der Laan, Nima S, Hejazi, Chuong, Huynh, Jacqueline, Miller, Hana M, El Sahly, Lindsey R, Baden, Mira, Baron, Luis, De La Cruz, Cynthia, Gay, Spyros, Kalams, Colleen F, Kelley, Michele P, Andrasik, James G, Kublin, Lawrence, Corey, Kathleen M, Neuzil, Lindsay N, Carpp, Rolando, Pajon, Dean, Follmann, Ruben O, Donis, Richard A, Koup
Publikováno v:
Science. 375:43-50
Antibody levels predict vaccine efficacy Symptomatic COVID-19 infection can be prevented by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. A “correlate of protection” is a molecular biomarker to measure how much immunity i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc22f4d0da06c2d43b284913744b8080
https://doi.org/10.1126/science.abm3425
https://doi.org/10.1126/science.abm3425
Autor:
Youyi Fong, Ying Huang, Bhavesh Borate, Lars W P van der Laan, Wenbo Zhang, Lindsay N Carpp, Iksung Cho, Greg Glenn, Louis Fries, Raphael Gottardo, Peter B Gilbert
Publikováno v:
Open Forum Infectious Diseases. 10
Background Respiratory syncytial virus (RSV) can cause serious lung infections in young children and there is currently no available vaccine. Methods We used complementary statistical frameworks to analyze 4 RSV serology measurements in mothers and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53496b432c373b1cd4be9490acc7512c
https://doi.org/10.1093/ofid/ofac693
https://doi.org/10.1093/ofid/ofac693
Autor:
Youyi, Fong, Adrian B, McDermott, David, Benkeser, Sanne, Roels, Daniel J, Stieh, An, Vandebosch, Mathieu, Le Gars, Griet A, Van Roey, Christopher R, Houchens, Karen, Martins, Lakshmi, Jayashankar, Flora, Castellino, Obrimpong, Amoa-Awua, Manjula, Basappa, Britta, Flach, Bob C, Lin, Christopher, Moore, Mursal, Naisan, Muhammed, Naqvi, Sandeep, Narpala, Sarah, O'Connell, Allen, Mueller, Leo, Serebryannyy, Mike, Castro, Jennifer, Wang, Christos J, Petropoulos, Alex, Luedtke, Ollivier, Hyrien, Yiwen, Lu, Chenchen, Yu, Bhavesh, Borate, Lars W P, van der Laan, Nima S, Hejazi, Avi, Kenny, Marco, Carone, Daniel N, Wolfe, Jerald, Sadoff, Glenda E, Gray, Beatriz, Grinsztejn, Paul A, Goepfert, Susan J, Little, Leonardo, Paiva de Sousa, Rebone, Maboa, April K, Randhawa, Michele P, Andrasik, Jenny, Hendriks, Carla, Truyers, Frank, Struyf, Hanneke, Schuitemaker, Macaya, Douoguih, James G, Kublin, Lawrence, Corey, Kathleen M, Neuzil, Lindsay N, Carpp, Dean, Follmann, Peter B, Gilbert, Richard A, Koup, Ruben O, Donis
Publikováno v:
Nature microbiology. 7(12)
Measuring immune correlates of disease acquisition and protection in the context of a clinical trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing antibody measurements 4 weeks post vaccination as correlates of r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::43118061614e503632a84f1faf847fce
https://pubmed.ncbi.nlm.nih.gov/35441174
https://pubmed.ncbi.nlm.nih.gov/35441174
Autor:
Youyi, Fong, Adrian B, McDermott, David, Benkeser, Sanne, Roels, Daniel J, Stieh, An, Vandebosch, Mathieu Le, Gars, Griet A, Van Roey, Christopher R, Houchens, Karen, Martins, Lakshmi, Jayashankar, Flora, Castellino, Obrimpong, Amoa-Awua, Manjula, Basappa, Britta, Flach, Bob C, Lin, Christopher, Moore, Mursal, Naisan, Muhammed, Naqvi, Sandeep, Narpala, Sarah, O'Connell, Allen, Mueller, Leo, Serebryannyy, Mike, Castro, Jennifer, Wang, Christos J, Petropoulos, Alex, Luedtke, Ollivier, Hyrien, Yiwen, Lu, Chenchen, Yu, Bhavesh, Borate, Lars W P, van der Laan, Nima S, Hejazi, Avi, Kenny, Marco, Carone, Daniel N, Wolfe, Jerald, Sadoff, Glenda E, Gray, Beatriz, Grinsztejn, Paul A, Goepfert, Susan J, Little, Leonardo Paiva, de Sousa, Rebone, Maboa, April K, Randhawa, Michele P, Andrasik, Jenny, Hendriks, Carla, Truyers, Frank, Struyf, Hanneke, Schuitemaker, Macaya, Douoguih, James G, Kublin, Lawrence, Corey, Kathleen M, Neuzil, Lindsay N, Carpp, Dean, Follmann, Peter B, Gilbert, Richard A, Koup, Ruben O, Donis
Publikováno v:
medRxiv : the preprint server for health sciences.
Anti-spike IgG binding antibody, anti-receptor binding domain IgG antibody, and pseudovirus neutralizing antibody measurements four weeks post-vaccination were assessed as correlates of risk of moderate to severe-critical COVID-19 outcomes through 83
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b99303cefddbdc9cc72f7a7744e3c4ce
https://pubmed.ncbi.nlm.nih.gov/36357712
https://pubmed.ncbi.nlm.nih.gov/36357712
Autor:
Michele P. Andrasik, Weiping Deng, Yiwen Lu, Bob C. Lin, Ruben O. Donis, Youyi Fong, Mira Baron, Lindsay N. Carpp, Lars W. P. van der Laan, Immune Assays Team, Adrian B. McDermott, Karen Martins, Lindsey R. Baden, Flora Castellino, James G. Kublin, Luis De La Cruz, Honghong Zhou, Chuong Huynh, Rolando Pajon, Amanda Eaton, David Benkeser, Mark Kutner, Dean Follmann, Marcella Sarzotti-Kelsoe, CoVPN Biostatistics Team, Hana M. El Sahly, Charlene McDanal, Jacqueline Miller, Christopher R. Houchens, Nima S. Hejazi, Kathleen M. Neuzil, Spyros A. Kalams, Bhavesh Borate, Coronavirus Efficacy (Cove) Team, David C. Montefiori, Lakshmi Jayashankar, Colleen F. Kelley, Richard A. Koup, Britta Flach, Peter B. Gilbert, Lawrence Corey, Chenchen Yu
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 4
article-version (status) pre
article-version (number) 4
BackgroundIn the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ffccfeae7ead57a33edd54278a0c324
https://doi.org/10.1101/2021.08.09.21261290
https://doi.org/10.1101/2021.08.09.21261290
